Market Research Logo

Crossject SA (ALCJ) - Product Pipeline Analysis, 2016 Update

Summary

Crossject SA (Crossject) is a medical device company that develops needle-free, pre-filled, single-use and fixed dose injection system based on chemicals and biologics. The company’s products include methotrexate, epinephrin, sumatriptan, L15, naloxone, apomorphine, and midazolam. It uses its needle-free injection system to develop a pipeline of supergenerics by combining drug molecules with zeneo. Crossject’s zeneo is the exclusive needle-free injection system that can deliver drugs intradermally, subcutaneously and intramuscularly. The company develops supergenerics in the therapeutic area of rheumatoid arthritis, anaphylactic shock and acute migraine. It markets its products through its network of distributors. Crossject is headquartered in Chenove, France.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Crossject SA
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio


Crossject SA Company Snapshot
Crossject SA Company Overview
Crossject SA Pipeline Products and Clinical Trials Overview
Crossject SA – Pipeline Analysis Overview
Key Facts
Crossject SA - Major Products and Services
Crossject SA Pipeline Products by Development Stage
Crossject SA Pipeline Products Overview
Zeneo ID Human Needle-Free Injection Device
Zeneo ID Human Needle-Free Injection Device Product Overview
Zeneo IM 0.5ml Needle - Free Injection Device
Zeneo IM 0.5ml Needle - Free Injection Device Product Overview
Zeneo SC 0.5ml Needle-Free Injection Device
Zeneo SC 0.5ml Needle-Free Injection Device Product Overview
Zeneo SC 0.8ml Needle-Free Injection Device
Zeneo SC 0.8ml Needle-Free Injection Device Product Overview
Zeneo SC High Viscosity Needle-Free Injection Device
Zeneo SC High Viscosity Needle-Free Injection Device Product Overview
Crossject SA - Key Competitors
Crossject SA - Key Employees
Crossject SA - Locations And Subsidiaries
Head Office
Recent Developments
Crossject SA, Recent Developments
Jul 16, 2015: CROSSJECT confirms the development plan for ZENEO Sumatriptan
Nov 24, 2014: Crossject Reports Positive Results From Bioequivalence Study With Needle Free ZENEO Methrotrexate
Oct 13, 2014: Crossject Appoints Henri de Parseval as Supply Chain Director
Jul 07, 2014: CROSSJECT launches bioequivalence clinical study with ZENEO Methrotrexate
Dec 09, 2013: Crossject develops a novel version of ZENEO, its needle-free injection device, specifically for patients with rheumatoid arthritis in conjunction with AFP
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Crossject SA Pipeline Products and Clinical Trials Overview
Crossject SA Pipeline Products by Equipment Type
Crossject SA, Key Facts
Crossject SA, Major Products and Services
Crossject SA Number of Pipeline Products by Development Stage
Crossject SA Pipeline Products Summary by Development Stage
Zeneo ID Human Needle-Free Injection Device - Product Status
Zeneo ID Human Needle-Free Injection Device - Product Description
Zeneo IM 0.5ml Needle - Free Injection Device - Product Status
Zeneo IM 0.5ml Needle - Free Injection Device - Product Description
Zeneo SC 0.5ml Needle-Free Injection Device - Product Status
Zeneo SC 0.5ml Needle-Free Injection Device - Product Description
Zeneo SC 0.8ml Needle-Free Injection Device - Product Status
Zeneo SC 0.8ml Needle-Free Injection Device - Product Description
Zeneo SC High Viscosity Needle-Free Injection Device - Product Status
Zeneo SC High Viscosity Needle-Free Injection Device - Product Description
Crossject SA, Key Employees
List of Figures
Crossject SA Pipeline Products by Equipment Type
Crossject SA Pipeline Products by Development Stage

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report